Prescription Drugs - Tajikistan

Tajikistan

In Tajikistan, the revenue in the Prescription Drugs market is estimated to reach US$38.52m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.41%, leading to a market volume of US$41.31m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, with US$358.90bn in 2024.
Looking at the per person figures, in Tajikistan, the revenue generated per person in 2024 is US$3.73.
Tajikistan's prescription drug market is experiencing a surge in demand due to an aging population and increasing prevalence of chronic diseases.

Key regions: Japan, China, Europe, Australia, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Prescription Drugs (Pharmacies) market in Tajikistan is experiencing significant growth and development due to various factors.

Customer preferences: Customers in Tajikistan have shown a growing preference for prescription drugs, leading to an increased demand for pharmacies. This can be attributed to several factors, including a rise in chronic diseases, an aging population, and an increase in disposable income. As people become more aware of the importance of healthcare and the need for prescription drugs, they are seeking out pharmacies to meet their medical needs.

Trends in the market: One of the key trends in the Prescription Drugs (Pharmacies) market in Tajikistan is the expansion of pharmacy chains. This trend can be seen in response to the growing demand for prescription drugs. Pharmacy chains are able to offer a wider range of products and services, including over-the-counter medications, health supplements, and healthcare consultations. This allows customers to conveniently access a variety of healthcare products and services in one location. Another trend in the market is the increased availability of generic drugs. Generic drugs are more affordable than branded drugs, making them a popular choice among customers. The government of Tajikistan has also taken steps to promote the use of generic drugs by implementing policies that encourage their production and distribution. This has led to a wider range of generic drugs being available in pharmacies, further driving the growth of the market.

Local special circumstances: Tajikistan is a developing country with a growing healthcare sector. The government has been actively investing in healthcare infrastructure and services, which has contributed to the growth of the Prescription Drugs (Pharmacies) market. Additionally, the country has a high burden of chronic diseases, such as cardiovascular diseases and diabetes, which has increased the demand for prescription drugs.

Underlying macroeconomic factors: The growth of the Prescription Drugs (Pharmacies) market in Tajikistan is also influenced by underlying macroeconomic factors. The country has experienced steady economic growth in recent years, resulting in an increase in disposable income. This has allowed more people to afford prescription drugs and contribute to the growth of the market. Furthermore, the government has implemented policies to improve access to healthcare services, including prescription drugs. This includes the implementation of a national health insurance system, which provides coverage for prescription drugs. Such initiatives have increased the affordability and accessibility of prescription drugs, further driving the growth of the market. In conclusion, the Prescription Drugs (Pharmacies) market in Tajikistan is developing due to customer preferences for prescription drugs, the expansion of pharmacy chains, the availability of generic drugs, local special circumstances such as a growing healthcare sector and high burden of chronic diseases, and underlying macroeconomic factors such as economic growth and government policies. These factors combined have created a favorable environment for the growth and development of the market.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.